First Eagle Investment Management LLC reduced its position in shares of CryoPort, Inc. (NASDAQ:CYRX – Free Report) by 50.1% in the third quarter, HoldingsChannel.com reports. The firm owned 1,268,924 shares of the company’s stock after selling 1,273,924 shares during the period. First Eagle Investment Management LLC’s holdings in CryoPort were worth $22,079,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. White Pine Capital LLC bought a new position in CryoPort during the 3rd quarter valued at approximately $539,000. Royce & Associates LP bought a new position in shares of CryoPort during the third quarter valued at approximately $7,073,000. Diversified Trust Co raised its holdings in shares of CryoPort by 3.4% during the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock valued at $344,000 after acquiring an additional 657 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of CryoPort by 376.7% during the third quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock valued at $6,943,000 after acquiring an additional 315,343 shares in the last quarter. Finally, State of Wyoming purchased a new stake in CryoPort in the third quarter worth $81,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Daniel Hancock sold 74,379 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the sale, the director owned 69,052 shares of the company’s stock, valued at $1,395,540.92. The trade was a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark W. Sawicki sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total transaction of $199,300.00. Following the transaction, the insider directly owned 92,356 shares of the company’s stock, valued at $1,840,655.08. This represents a 9.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.50% of the stock is owned by company insiders.
CryoPort Stock Down 0.3%
Shares of CYRX stock opened at $19.74 on Wednesday. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -20.35 and a beta of 1.89. The business’s fifty day moving average is $17.60 and its 200 day moving average is $13.80. CryoPort, Inc. has a twelve month low of $7.61 and a twelve month high of $21.78.
CryoPort (NASDAQ:CYRX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $50.22 million during the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. Equities research analysts expect that CryoPort, Inc. will post -0.88 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently weighed in on the stock. BTIG Research lifted their price target on shares of CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Weiss Ratings upgraded shares of CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Piper Sandler upgraded shares of CryoPort to a “buy” rating in a report on Tuesday, October 13th. Robert W. Baird set a $26.00 target price on shares of CryoPort in a research report on Tuesday, October 13th. Finally, Roth Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of CryoPort in a research note on Friday, August 7th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $21.69.
View Our Latest Research Report on CryoPort
CryoPort Profile
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Featured Articles
- Five stocks we like better than CryoPort
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort, Inc. (NASDAQ:CYRX – Free Report).
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
